The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells

被引:50
|
作者
Fey, Dirk [1 ,2 ]
Matallanas, David [1 ,2 ]
Rauch, Jens [1 ,2 ]
Rukhlenko, Oleksii S. [1 ,2 ]
Kholodenko, Boris N. [1 ,2 ]
机构
[1] Univ Coll Dublin, UCD Sch Med, Syst Biol Ireland, Dublin 4, Ireland
[2] Univ Coll Dublin, Conway Inst, Dublin 4, Ireland
基金
欧盟地平线“2020”; 爱尔兰科学基金会;
关键词
Systems biology; Dynamic modelling; MAPK cascade; ONCOGENIC K-RAS; WILD-TYPE RAS; N-RAS; NEGATIVE FEEDBACK; FATE DECISIONS; MAPK PATHWAY; H-RAS; INHIBITOR RESISTANCE; MST2; PATHWAY; KINASE;
D O I
10.1016/j.semcdb.2016.06.011
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The intricate dynamic control and plasticity of RAS to ERK mitogenic, survival and apoptotic signalling has mystified researches for more than 30 years. Therapeutics targeting the oncogenic aberrations within this pathway often yield unsatisfactory, even undesired results, as in the case of paradoxical ERK activation in response to RAF inhibition. A direct approach of inhibiting single oncogenic proteins misses the dynamic network context governing the network signal processing. In this review, we discuss the signalling behaviour of RAS and RAF proteins in normal and in cancer cells, and the emerging systems-level properties of the RAS-to-ERK signalling network. We argue that to understand the dynamic complexities of this control system, mathematical models including mechanistic detail are required. Looking into the future, these dynamic models will build the foundation upon which more effective, rational approaches to cancer therapy will be developed. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:96 / 107
页数:12
相关论文
共 50 条
  • [1] Targeting RAS–ERK signalling in cancer: promises and challenges
    Ahmed A. Samatar
    Poulikos I. Poulikakos
    Nature Reviews Drug Discovery, 2014, 13 : 928 - 942
  • [2] Apicobasal polarity and Ras/Raf/MEK/ERK signalling in cancer
    Peng, Juan
    Gassama-Diagne, Ama
    GUT, 2017, 66 (06) : 984 - +
  • [3] Targeting RAS-ERK signalling in cancer: promises and challenges
    Samatar, Ahmed A.
    Poulikakos, Poulikos I.
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (12) : 928 - +
  • [4] Effects of protolichesterinic acid, a lichen compound, on the ERK1/ERK2 signalling pathway in cancer cells and normal endothelial cells
    Bessadottir, M.
    Bjornsdottir, A.
    Omarsdottir, S.
    Ogmundsdottir, H. M.
    PLANTA MEDICA, 2008, 74 (09) : 1022 - 1022
  • [5] Regulation of ERK signalling by DUSP4 in intestinal cancer cells
    Rivard, Nathalie
    Cagnol, Sebastien
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 28 : S17 - S17
  • [6] The MEK/ERK Pathway Promotes NOTCH Signalling in Pancreatic Cancer Cells
    Tremblay, Isabelle
    Pare, Emanuel
    Arsenault, Dominique
    Douziech, Melanie
    Boucher, Marie-Josee
    PLOS ONE, 2013, 8 (12):
  • [7] Influence of Ras-signalling on the expression profile of pancreatic cancer cells
    Fensterer, H
    Giehl, K
    Buchholz, M
    Adler, G
    Gress, TM
    GASTROENTEROLOGY, 2002, 122 (04) : A491 - A491
  • [8] Annexin A6 inhibits Ras signalling in breast cancer cells
    Vila de Muga, S.
    Timpson, P.
    Cubells, L.
    Evans, R.
    Hayes, T. E.
    Rentero, C.
    Hegemann, A.
    Reverter, M.
    Leschner, J.
    Pol, A.
    Tebar, F.
    Daly, R. J.
    Enrich, C.
    Grewal, T.
    ONCOGENE, 2009, 28 (03) : 363 - 377
  • [9] Annexin A6 inhibits Ras signalling in breast cancer cells
    S Vilá de Muga
    P Timpson
    L Cubells
    R Evans
    T E Hayes
    C Rentero
    A Hegemann
    M Reverter
    J Leschner
    A Pol
    F Tebar
    R J Daly
    C Enrich
    T Grewal
    Oncogene, 2009, 28 : 363 - 377
  • [10] MyD88 is required for RAS/ERK mediated cell survival in cancer cells
    Kfoury, Alain
    Coste, Isabelle
    Le Corf, Katy
    El Sabeh, Rana
    Renno, Toufic
    BULLETIN DU CANCER, 2011, 98 : S51 - S52